The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients

The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients - The comparison of azilsartan and amlodipine for treatment of VEGFR-TKI-induced hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010940

Enrollment

Registered

2013-06-12

Start date

2013-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VEGFR-TKI-induced hypertension

Interventions

Azilsartan amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. pathologically diagnosed as cancer or sarcoma 2. no aplication for radical treatment because of locally advanced or metastatic disease 3. patients know their diagnosis and status 4. undergoing VEGFR-TKI treatment 5. without hypertension at the start of VEGFR-TKI 6. without anti-hypertensive at the start of VEGFR-TKI 7. newly arisen hypertension (systolic >140mmHg and increase 20mmHg starting VEGFR-TKI compared with before VEGFR-TKI treatment 8. obtained informed concent by document

Exclusion criteria

Exclusion criteria: 1. < 20 year-old 2. Cr>3.0mg/dl or eGFR<15ml/min 3. bilateral renal arterial stenosis or unilateral renal rterial stenosis in solitary kidney 4. allergy to angiotensin 2 receptor blockers or calcium channel blockers and patients who were thought as inadequate for this study by doctor in charge

Design outcomes

Primary

Measure	Time frame
The comparison of the efficacy between azilsartan group and amlodipine group	—

Countries

Japan

Contacts

Public ContactIzumi, Kouji

Kanazawa University Department of Urology

azuizu2003@yahoo.co.jp076-265-2393

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026